{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:13:18Z","timestamp":1779289998217,"version":"3.51.4"},"reference-count":45,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with skin and\/or nail psoriasis. As suggested in 2012 by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), studies devoted to assess cancer in the PsA population are still limited and need to be increased. Therefore, the aim of this study was to determine the incidence of malignancies in patients with PsA who are taking conventional and biologic therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A cohort of patients with PsA was followed prospectively. At first visit, as well as at each 3\u20134 month followup visit, according to standardized clinical practice, medical history, and physical and laboratory findings were recorded. Information on the presence of comorbidities, as well as malignancies, was collected. At each visit, data were recorded on radiography and pathology, confirming malignancy diagnosis, when present.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 618 patients with PsA were included in the study. In particular, 296 were taking anti-tumor necrosis factor-\u03b1 (anti-TNF) agents and 322 were taking disease-modifying antirheumatic drugs (DMARD). During the observation period, in the total group, 44 patients (7.1%) had a diagnosis of malignancy. Of them, 14 (4.7%; 95% CI 2.8\u20137.8; 0.52\/100 patient-yrs) received anti-TNF therapy and 30 (9.3%; 95% CI 6.6\u201313.0; 1.03\/100 patient-yrs) received traditional DMARD (p = 0.019). However, after adjusting for major demographic and clinical characteristics, the difference between the 2 treatments was no longer significant (p = 0.480), and the only predictor of malignancy occurrence was age (HR 1.04, 95% CI 1.009\u20131.073, p = 0.012).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Data from this study confirm that biological therapies do not lead to any increased risk for cancer development, when adequately administered and with proper followup.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160542","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T02:04:02Z","timestamp":1473991442000},"page":"2149-2154","source":"Crossref","is-referenced-by-count":30,"title":["Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study"],"prefix":"10.3899","volume":"43","author":[{"given":"Luisa","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Del Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Nicola Dario","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"2018112909362986000_43.12.2149.1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"2018112909362986000_43.12.2149.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120243"},{"key":"2018112909362986000_43.12.2149.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1892-1"},{"key":"2018112909362986000_43.12.2149.4","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/rheumatology\/kes213","article-title":"Increase in ventricular-arterial stiffness in patients with psoriatic arthritis","volume":"51","author":"Shang","year":"2015","journal-title":"Rheumatology"},{"key":"2018112909362986000_43.12.2149.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140021"},{"key":"2018112909362986000_43.12.2149.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.3.210"},{"key":"2018112909362986000_43.12.2149.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2018112909362986000_43.12.2149.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110845"},{"key":"2018112909362986000_43.12.2149.9","doi-asserted-by":"publisher","DOI":"10.2174\/187152811304140915152102"},{"key":"2018112909362986000_43.12.2149.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(03)00048-X"},{"key":"2018112909362986000_43.12.2149.11","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8307-1"},{"key":"2018112909362986000_43.12.2149.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8481-0"},{"key":"2018112909362986000_43.12.2149.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.06.016"},{"key":"2018112909362986000_43.12.2149.14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s10067-015-3002-2","article-title":"Transcriptional network profile on synovial fluid T cells in psoriatic arthritis","volume":"34","author":"Fiocco","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2018112909362986000_43.12.2149.15","first-page":"S28","article-title":"Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology","volume":"29","author":"Salvarani","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909362986000_43.12.2149.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2018112909362986000_43.12.2149.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130458"},{"key":"2018112909362986000_43.12.2149.18","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982\u20131991","volume":"27","author":"Shbeeb","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909362986000_43.12.2149.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.23185"},{"key":"2018112909362986000_43.12.2149.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37740"},{"key":"2018112909362986000_43.12.2149.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02655.x"},{"key":"2018112909362986000_43.12.2149.22","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01520.x"},{"key":"2018112909362986000_43.12.2149.23","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"2018112909362986000_43.12.2149.24","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1425"},{"key":"2018112909362986000_43.12.2149.25","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.9.1132"},{"key":"2018112909362986000_43.12.2149.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04520.x"},{"key":"2018112909362986000_43.12.2149.27","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124618"},{"key":"2018112909362986000_43.12.2149.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06179-7"},{"key":"2018112909362986000_43.12.2149.29","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van L\u00fcmig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2018112909362986000_43.12.2149.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.24506"},{"key":"2018112909362986000_43.12.2149.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"2018112909362986000_43.12.2149.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep423"},{"key":"2018112909362986000_43.12.2149.33","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909362986000_43.12.2149.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.08.005"},{"key":"2018112909362986000_43.12.2149.35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","article-title":"Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2018112909362986000_43.12.2149.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.019"},{"key":"2018112909362986000_43.12.2149.37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.214585"},{"key":"2018112909362986000_43.12.2149.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.06.112"},{"key":"2018112909362986000_43.12.2149.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2536-z"},{"key":"2018112909362986000_43.12.2149.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2378-0"},{"key":"2018112909362986000_43.12.2149.41","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm"},{"key":"2018112909362986000_43.12.2149.42","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7867"},{"key":"2018112909362986000_43.12.2149.43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1756-185X.12467","article-title":"The long-term effects of anti-TNF-\u03b1 agents on patients with chronic viral hepatitis C and B infections","volume":"18","author":"Temel","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2018112909362986000_43.12.2149.44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/14712598.2015.1011616","article-title":"Current evidence in the field of the management with TNF-\u03b1 inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection","volume":"15","author":"Caso","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"2018112909362986000_43.12.2149.45","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1306433"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:18:27Z","timestamp":1692505107000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,1]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3899\/jrheum.160542"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160542","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}